Discrimination between COPD patients with and without alpha 1‐antitrypsin deficiency using an electronic nose

Hattesohl, Akira; Jörres, Rudolf A.; Dressel, Holger; Schmid, Severin; Vogelmeier, Claus; Greulich, Timm; Noeske, Sarah; Bals, Robert; Koczulla, Andreas Rembert

doi:10.1111/j.1440-1843.2011.02047.x

Cited by 58 publications

(46 citation statements)

References 34 publications

(83 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hattesohl et al demonstrated that eNose derived VOCs profiles were not different between COPD patients with and without an alpha 1-antitrypsin (AAT) deficiency, after internal cross-validation. Moreover, cross-validated VOCs profiles of AAT deficiency patients did not differ after human recombinant AAT therapy [28]. …”

Section: Resultsmentioning

confidence: 99%

Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review

et al. 2012

View full text Add to dashboard Cite

There is an increasing interest in the potential of exhaled biomarkers, such as volatile organic compounds (VOCs), to improve accurate diagnoses and management decisions in pulmonary diseases. The objective of this manuscript is to systematically review the current knowledge on exhaled VOCs with respect to their potential clinical use in asthma, lung cancer, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and respiratory tract infections. A systematic literature search was performed in PubMed, EMBASE, Cochrane database, and reference lists of retrieved studies. Controlled, clinical, English-language studies exploring the diagnostic and monitoring value of VOCs in asthma, COPD, CF, lung cancer and respiratory tract infections were included. Data on study design, setting, participant characteristics, VOCs techniques, and outcome measures were extracted. Seventy-three studies were included, counting in total 3,952 patients and 2,973 healthy controls. The collection and analysis of exhaled VOCs is non-invasive and could be easily applied in the broad range of patients, including subjects with severe disease and children. Various research groups demonstrated that VOCs profiles could accurately distinguish patients with a pulmonary disease from healthy controls. Pulmonary diseases seem to be characterized by a disease specific breath-print, as distinct profiles were found in patients with dissimilar diseases. The heterogeneity of studies challenged the inter-laboratory comparability. In conclusion, profiles of VOCs are potentially able to accurately diagnose various pulmonary diseases. Despite these promising findings, multiple challenges such as further standardization and validation of the diverse techniques need to be mastered before VOCs can be applied into clinical practice.

show abstract

Section: Resultsmentioning

confidence: 99%

Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review

et al. 2012

View full text Add to dashboard Cite

show abstract

“…In principle, the diagnosis of ear, nose and throat infections [28] or pneumonia [29] is possible. Moreover, patients with lung cancer [30], asthma [31], COPD [18] or a 1 -AT deficiency [20] could be recognised when compared with healthy controls or individuals with other respiratory diseases. In our study, we aimed to test the hypothesis that OSAS could be recognised by its VOC profile and that the profile would change after CPAP treatment.…”

Section: Discussionmentioning

confidence: 99%

“…The participants breathed medicinal air (Aer medicinalis Linde; Linde Gas Therapeutics GmbH, Unterschleibheim, Germany) and exhaled for 10 s at a flow rate of 100-200 mL?s -1 into a disposable collection bag, which then was assessed within 60 s. This medicinal air was also used as reference air for the 60-s baseline, followed by a 60-s sample draw from the collection bag, and completed by a 60-s purging of the electronic nose. These measurements were performed in triplicate [20].…”

Section: Electronic Nosementioning

confidence: 99%

“…Instead of identifying single compounds, the assessment of exhaled breath can also be performed by devices enabling the recognition of patterns of VOCs [17]. Indeed, such devices can distinguish between a number of diseases via their VOC profiles [18][19][20]. A recent review article summarising potential medical applications has been published elsewhere [21].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Detection of obstructive sleep apnoea by an electronic nose

et al. 2012

Self Cite

View full text Add to dashboard Cite

Diagnosis of obstructive sleep apnoea syndrome (OSAS) is technically demanding, costintensive and time-consuming. The measurement of volatile organic compounds by an electronic nose is an innovative method that determines distinct molecular patterns of exhaled breath in different patient groups. We addressed the following questions: What is the diagnostic accuracy of an electronic nose in the detection of OSAS and the ability to detect effects of standard therapy in patients with OSAS? Are these results related to changes in distinct markers of airway inflammation and extracellular remodelling?We included 40 OSAS patients and 20 healthy controls. Exhaled breath of all participants was analysed using the Cyranose 320 electronic nose. Pharyngeal washings were performed to sample the upper airway compartment. For statistical analysis linear discriminant analysis was employed.We identified a linear discriminant function separating OSAS from control (p,0.0001). The corresponding area under the receiver-operating curve was 0.85 (95% CI 0.75-0.96; sensitivity 0.93 and specificity 0.7). In pharyngeal washing fluids of OSAS patients, we observed higher levels of a 1 -antitrypsin and markers of extracellular remodelling compared to controls.The electronic nose can distinguish between OSAS patients and controls with high accuracy. @ERSpublicationsThe electronic nose can distinguish between OSAS patients and controls with high accuracy

show abstract

“…Electronic noses have been applied to various analysis fields such as food [33,34] and various diseases; diabetes [35], uremia [36], asthma [37], chronic obstructive pulmonary disease [38], pulmonary sarcoidosis [39], colorectal cancer [40], and malignant mesothelioma [41,42]. The application of electronic noses to detect lung cancer was also proposed.…”

Section: Discussionmentioning

confidence: 99%

Analysis of volatile organic compounds in exhaled breath for lung cancer diagnosis using a sensor system

Chang

Lee

Ban

et al. 2018

Sensors and Actuators B: Chemical

122

View full text Add to dashboard Cite

Discrimination between COPD patients with and without alpha 1‐antitrypsin deficiency using an electronic nose

Abstract: An electronic nose can detect differences in smell prints of COPD patients with and without AAT deficiency. Augmentation therapy changes the volatile organic compound pattern. The electronic nose may be helpful in the diagnosis of AAT deficiency.

Cited by 58 publications

References 34 publications

Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review

Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review

Detection of obstructive sleep apnoea by an electronic nose

Analysis of volatile organic compounds in exhaled breath for lung cancer diagnosis using a sensor system

Contact Info

Product

Resources

About